Compare HubSpot Inc (HUBS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs BIO-TECHNE Corp — how do they compare? HubSpot Inc trades at $220.7 (market cap $10.77B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: HubSpot Inc and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| HUBS | TECH | |
|---|---|---|
Market Cap | $10.77B | $11.24B |
Sector | Technology | Health |
52-Week High | $522.97 | $72.29 |
52-Week Low | $170.39 | $43.31 |
Enterprise Value | $9.67B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $210.35, up 3.91% today, but remains in a bearish technical trend with strong selling pressure on moving averages. The company shows solid revenue growth with Q2 2026 earnings beating estimates at $3.26 EPS, though recent guidance cuts and a securities fraud investigation have created significant volatility. Fundamentals reveal strong gross margins of 83.25% but modest net income margins of 4.26%, with valuation metrics indicating premium pricing at P/E 74.89 and P/S 3.22.
The outlook is mixed with 76.59% analyst buy ratings and a $233.93 consensus target suggesting 11% upside, but near-term risks from customer growth slowdown and legal challenges weigh on sentiment. Long-term AI transformation strategy offers potential, but execution risks and competitive pressures require careful monitoring for investors considering entry at current levels.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
